A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): A pilot study

International Journal of Antimicrobial Agents

Volumn 17, Issue 1, 2001, Pages 67-70

  Thakur, C P ^a  

^a PATNA MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Ambisome; Kala azar; Single dose

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; LEISHMANIASIS; MALE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CHILD; DRUG COSTS; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0035189327     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(00)00312-5     Document Type: Article

References (25)

1. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India justify its continued use as a first line drug? An observational study of 80 cases
2. Treatment of visceral leishmaniasis: Current status
3. Therapeutic use of sodium stibogluconate in Kala-azar from some hyperendemic districts of north Bihar (India)
4. Comparison of regimes of antimony resistant kala-azar patients: A randomised study
5. Diminishing effectiveness of currently used drugs in the treatment of kala-azar and amphotericin B in antimony and pentamidine resistant kala-azar
6. Amphotericin B in resistant kala-azar in Bihar
7. Amphotericin B for second line treatment of Indian kala-azar
8. Use of amphotericin B in drug resistant cases of visceral leishmaniasis in North Bihar; India
9. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar
10. Amphotericin B deoxycholate treatment of visecral leishmaniasis with newer modes of administration and precaution, a study of 938 cases
11. Amphotericin B: 30 years of clinical experience
12. Amphotericin B toxicity
13. A pharmacological guide to the clinical use of amphotericin B
14. Comparison of the treatment regimens with liposomal amphotericin (Ambisome) for visceral leishmaniasis in India. A randomised dose finding study
15. Efficacy, safety of liposomal amphotericin B (Ambisome) for visceral leishmaniasis in endemic developing countries
16. Short course treatment of visceral leishmaniasis with lipsomal amphotericin B (Ambisome)
17. Activity of lipsomal amphotericin B (Ambisome) against Leishmania infantum and tissue distribution in mice
18. Daily versus alternate day regimen of amphotericin B in the treatment of kala-azar: A randomised comparison
19. Two hour versus six hour administration of amphotericin B required in the treatment of kala-azar
20. Are incremental dose of amphotericin B required for the treatment of visceral leishmaniasis?
21. Comparison of regimens of amphotericin B deoxycholate in kala-azar
22. Correction of Serum electrolytes imbalance prevents cardiac arrythmia during amphotericin B administration
23. Sodium antimony gluconate, amphotericin and myocardial damage
24. Liposomal Amphotericin B (Ambisome) in the treatment of complicated kala-azar under field conditions
25. Comparative safety, tolerance and pharmacokinetic of Amphotericin B lipid complex and Amphotericin B Deoxycholate in healthy male volunteers